An LNP-mRNA vaccine modulates innate cell trafficking and promotes polyfunctional Th1 CD4⁺ T cell responses to enhance BCG-induced protective immunity against Mycobacterium tuberculosis.

ABSTRACT:

Background

Mycobacterium tuberculosis remains the largest infectious cause of mortality worldwide, even with over a century of widespread administration of the only licenced tuberculosis (TB) vaccine, Bacillus Calmette-Guérin (BCG). mRNA technology remains an underexplored approach for combating chronic bacterial infections such as TB.

Methods

We have developed a lipid nanoparticle (LNP)-mRNA vaccine, termed mRNA^CV2, encoding for the M. tuberculosis CysVac2 fusion protein, which we have previously formulated as an adjuvanted subunit vaccine. This LNP-mRNA vaccine was administered intramuscularly to female C57BL/6 mice as a standalone vaccine or as booster to BCG to assess immunogenicity and efficacy of the construct.

Findings

Vaccination with mRNA^CV2</

SUBMITTER: Lukeman H 

PROVIDER: S-EPMC11871481 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature